Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of personality on likelihood of contracting SARS-CoV-2 in the United States.

Personality and individual differences·2026
Same author

Expanded Tox21 Biological Assay Panel for the Prediction of Drug-Induced Liver Injury and Cardiotoxicity.

Environmental health perspectives·2026
Same author

ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.

Nature communications·2026
Same author

Early-stage drug discovery in a new-generation ultrahigh-throughput mass spectrometry platform.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Jun 6, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.

Michele Ceribelli1, Frances Anne Tosto1, Xiaohu Zhang1

  • 1Division of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850.

Proceedings of the National Academy of Sciences of the United States of America
|November 25, 2024
PubMed
Summary

This study shows that in vitro drug screening can identify synergistic combinations of targeted cancer therapies, like Venetoclax and Ibrutinib, for lymphoma treatment. These combinations effectively induce apoptosis and cell death, mirroring in vivo results.

Keywords:
cancer heterogeneitydrug combinationsdrug synergydrug translationlymphoma

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K

Related Experiment Videos

Last Updated: Jun 6, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.8K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Clinical cancer trials require strong mechanistic rationale and validated drug activity in disease models.
  • Phenotypic screening identifies drug activity but lacks optimization for multidrug regimens.

Purpose of the Study:

  • To evaluate in vitro drug screening for optimizing multidrug combinations in lymphoma.
  • To dissect the activity of Venetoclax, Ibrutinib, Prednisolone, and Lenalidomide in lymphoma cell lines.

Main Methods:

  • Utilized in vitro screening across lymphoma cell lines with four small-molecule drugs.
  • Developed a time-course assay for concurrent multidrug exposure.
  • Evaluated drug synergy, apoptosis, and cytotoxicity responses.

Main Results:

  • Synergistic drug combinations promoted apoptosis and cytotoxicity at in vivo-relevant concentrations.
  • Rapid, synergistic apoptosis induction was key to multicomponent targeted therapy activity.
  • Diffuse large B-cell lymphoma models showed heterogeneity in drug pair synergism.

Conclusions:

  • In vitro drug screening can identify synergistic multidrug combinations for cancer treatment.
  • Targeted therapy combinations exploit synergy to overcome tumor diversity.
  • Chemotherapy combinations showed limited benefit, driven by individual drug activity.